Table 1 Clinical characteristics of study cohorts.
From: Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survival
Characteristic | Discovery | Replication | Combined | P a |
|---|---|---|---|---|
Localized prostate cancer cohort | ||||
Patients, n | 246 | 212 | 458 | |
Age at diagnosis | 0.149 | |||
Median, y (IQR) | 65 (61–69) | 68 (62–71) | 66 (61–70) | |
PSA at diagnosis | <0.001 | |||
Median, ng/mL (IQR) | 10.1 (6.7–15.8) | 12.6 (7.6–19.8) | 11.1 (7.1–17.5) | |
≤20 | 192 (81.7) | 155 (76.0) | 347 (79.0) | |
>20 | 43 (18.3) | 49 (24.0) | 92 (21.0) | |
Pathologic Gleason score, n (%) | <0.001 | |||
≤7 | 217 (89.7) | 175 (82.9) | 392 (86.5) | |
>7 | 25 (10.3) | 36 (17.1) | 61 (13.5) | |
Pathologic stage, n (%) | <0.001 | |||
T1/T2 | 173 (72.4) | 130 (61.3) | 303 (67.2) | |
T3/T4/N1 | 66 (27.6) | 82 (38.7) | 148 (32.8) | |
BCR | 75 (30.5) | 109 (51.4) | 184 (40.2) | |
Median follow-up time b , mo (95% CI) | 50 (45–55) | 60 (56–64) | 54 (50–58) | |
Advanced prostate cancer cohort | ||||
Characteristic | P c | |||
Patients, n | 504 | |||
Age at diagnosis | 0.904 | |||
Median, y (IQR) | 73 (66–79) | |||
≤72 | 250 (49.6) | |||
>72 | 254 (50.4) | |||
PSA at ADT initiation | <0.001 | |||
Median, ng/mL (IQR) | 33.8 (9.3–133.3) | |||
Biopsy Gleason score at diagnosis, n (%) | <0.001 | |||
<7 | 139 (28.3) | |||
7 | 173 (35.2) | |||
>7 | 180 (36.6) | |||
Clinical stage at diagnosis, n (%) | <0.001 | |||
M0 | 308 (61.4) | |||
M1 | 194 (38.6) | |||
PSA nadir | <0.001 | |||
Median, ng/mL (IQR) | 0.14 (0.01–1.06) | |||
<0.2 | 275 (54.8) | |||
≥0.2 | 227 (45.2) | |||
Time to PSA nadir | <0.001 | |||
Median, mo (IQR) | 10 (5–20) | |||
Treatment modality | 0.002 | |||
ADT as primary treatment | 254 (50.5) | |||
ADT for post RP PSA failure | 73 (14.5) | |||
ADT for post RT PSA failure | 12 (2.4) | |||
Neoadjuvant/adjuvant ADT with RT | 122 (24.3) | |||
Others | 42 (8.3) | |||
PCSM | 94 (18.7) | |||
Median follow-up timeb, mo (95% CI) | 60 (57–63) | |||
